All Posts Tagged With: "EXEL"

(AKRX) Company News for June 07, 2011 – Corporate Summary

•    Share prices of home nursing provider Amedisys, Inc.(NASDAQ:AMED) fell 7.41% after CRT Capital reduced its earnings estimates for fiscal 2011

•    According to Canaccord Genuity, data from a trial of...

7Jun2011 | | 0 comments | Continued

(SNY) Sanofi-Aventis Announces Agreement to Acquire TargaGen

Sanofi-Aventis (SNY) continues to work on expanding its oncology portfolio with the company recently entering into an agreement to acquire TargaGen Inc. TargaGen, a privately-held US biopharmaceutical company,...

1Jul2010 | | 0 comments | Continued

(EXEL) Exelixis Presents Positive Drug Trial Data

Recently, Exelixis Pharma (EXEL) presented positive data from a mid-stage trial of its lead candidate, XL184. The drug, which is being co-developed with Bristol-Myers Squibb (

23May2010 | | 0 comments | Continued

(EXEL) Exelixis Pharma First Quarter Report Narrows Loss

Exelixis Pharma (EXEL) reported a first quarter loss per share of 25 cents, better than a loss of 34 cents in the year-ago period. However Incorporatedluding restructuring expenses of $16.1 million, loss...

17May2010 | | 0 comments | Continued